LOGIN  |  REGISTER
Chimerix

U.S. Physical Therapy to Present at the Stephens Annual Investment Conference and the 15th Annual Southwest IDEAS Investor Conference

November 09, 2023 | Last Trade: US$87.00 2.06 -2.31

HOUSTON / Nov 09, 2023 / Business Wire / U.S. Physical Therapy, Inc. (NYSE: USPH) (the “Company”), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chief Executive Officer, will participate in the Stephens Annual Investment Conference on Wednesday, November 15, 2023.

On the same day, Carey Hendrickson, Chief Financial Officer, and Eric Williams, Chief Operating Officer, will participate in the 15th Annual Southwest IDEAS Investor Conference. The presentations will cover an overview of the Company.

A copy of USPh’s investor presentation is posted on the Company’s website at www.usph.com.

About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 675 outpatient physical therapy clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 42 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

Recursion

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page